GRFS · Grifols SA ADR
United States · RS rating 34 · As of 2026-10-14
| Price | 7.24 USD |
|---|---|
| 1-day change | +1.0% |
| RS rating (overall / 1M / 3M / 12M) | 34 / 55 / 58 / 25 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 28 / 19 / 45 |
| Industry group (rank) | Medical-Ethical Drugs (91) |
| EPS growth Q/Q | +67.7% |
| Sales growth Q/Q | -4.3% |
| Distance from 52-week high | +25.7% |
| Market cap (USD) | $5.4B |